True North Labs

Author: labstruenorth@gmail.com

  • Merck Advances Oral Peptide Candidate Into Phase 1 Trial Using Cyprumed’s Delivery Technology

    Pharmaceutical giant Merck has begun a Phase 1 clinical trial for an oral peptide drug candidate built on technology developed by Swiss biotech company Cyprumed. This milestone represents meaningful progress in one of the most persistent challenges in peptide therapeutics: finding reliable ways to deliver these delicate molecules through oral administration rather than injection.

    Peptides have long shown promise as therapeutic agents due to their specificity and effectiveness, but many require injection because they can break down in the digestive system before reaching the bloodstream. Cyprumed has focused its research on overcoming this obstacle, developing proprietary technology designed to protect peptides as they pass through the gastrointestinal tract and improve their absorption. Merck’s decision to move forward with a Phase 1 trial using this technology suggests confidence in the platform’s potential to translate into a viable oral treatment option.

    Phase 1 trials represent an important early step in drug development, typically focusing on safety and how the body processes a new treatment in a small group of participants. While it’s still early in the development pathway, the initiation of this trial reflects growing momentum in the oral peptide space and highlights the value of specialized drug delivery technologies in expanding what’s possible with peptide-based medicine.

    If oral peptide delivery technologies like Cyprumed’s continue to prove successful, they could eventually make peptide therapies more convenient and accessible for patients who currently rely on injectable formulations. This could be particularly meaningful for individuals managing chronic conditions who require long-term treatment, as oral options may improve ease of use and treatment adherence over time.

    Collaborations like this one between established pharmaceutical companies and specialized biotech innovators often play a key role in advancing promising technologies toward real-world application. As this Phase 1 trial progresses, it will offer valuable early data on safety and tolerability, laying the groundwork for potential future trials. This news is for informational purposes only and is not medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Merck Starts Phase 1 Trial of Oral Peptide Developed With Cyprumed’s Technology – Yahoo Finance

  • New Clinical Trial Launches to Study Innovative Weight-Loss Peptide Combination for Type 2 Diabetes

    New Clinical Trial Launches to Study Innovative Weight-Loss Peptide Combination for Type 2 Diabetes

    A new clinical trial has been launched to investigate EloraTZP, an innovative coformulation combining eloralintide and tirzepatide, as a potential treatment for body weight reduction in adults living with obesity or overweight alongside type 2 diabetes. This study marks an exciting step forward in the ongoing exploration of peptide-based therapies for metabolic health.

    The trial aims to compare the efficacy and safety of this dual-peptide combination against tirzepatide alone, a treatment that has already shown significant promise in supporting weight management and blood sugar control. By studying how these two peptides work together, researchers hope to better understand whether combination therapies can offer enhanced benefits for patients navigating the complex challenges of obesity and type 2 diabetes.

    This research reflects a broader trend in the peptide therapeutics field, where scientists continue to explore innovative combinations that may provide more comprehensive metabolic support. Obesity and type 2 diabetes often occur together, and treatments that can address both conditions simultaneously could represent meaningful progress for patients seeking effective, science-backed options.

    With a planned duration of approximately two years, this study promises to generate valuable data on long-term outcomes, safety profiles, and the overall effectiveness of this new peptide coformulation. Longer-term studies like this one are particularly valuable because they help researchers understand how treatments perform over extended periods, which is crucial for conditions like obesity and diabetes that often require sustained management.

    The peptide research community continues to make strides in developing new tools to help people manage weight and metabolic health, and trials like this one play an essential role in that progress. As this study moves forward, it will contribute to the growing body of knowledge about how peptide combinations might offer new possibilities for patients and healthcare providers alike.

    This article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Clinical Trial: A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes

  • FDA Approves Foundayo™, Eli Lilly’s Convenient New Once-Daily GLP-1 Pill for Weight Loss

    FDA Approves Foundayo™, Eli Lilly’s Convenient New Once-Daily GLP-1 Pill for Weight Loss

    Eli Lilly has received FDA approval for Foundayo™ (orforglipron), marking a significant step forward in the accessibility of GLP-1 therapies for weight management. Unlike many existing oral medications in this class, Foundayo stands out for its remarkable flexibility: patients can take it at any time of day, without needing to time doses around meals or worry about water intake restrictions that have historically complicated other oral peptide-based treatments.

    This approval is particularly meaningful for people who have been hesitant to start GLP-1 therapy due to needle aversion or the logistical challenges of injectable regimens. Many current GLP-1 medications, while effective, require weekly injections and careful storage, which can be a barrier for some patients. Foundayo’s oral format and simplified dosing schedule could make it easier for a broader range of people to access and stick with a weight management plan recommended by their healthcare provider.

    The convenience factor also addresses a common pain point with other oral GLP-1 options currently on the market, which often require patients to take the medication on an empty stomach and wait a specific period before eating or drinking. By removing these restrictions, Lilly’s new formulation represents a meaningful innovation in how peptide-based therapies can be delivered, potentially improving adherence and real-world outcomes for patients managing weight-related health concerns.

    This development reflects the broader momentum in the GLP-1 space, where pharmaceutical companies continue to refine delivery methods to make effective treatments more accessible and user-friendly. As oral peptide technology advances, patients may increasingly have more choices that fit their lifestyles, whether that means avoiding injections altogether or simplifying complex dosing routines. The FDA’s approval of Foundayo signals continued regulatory confidence in orally administered GLP-1 medications as a viable and convenient option within the growing toolkit for weight management.

    As with any new medication, individuals interested in Foundayo should discuss whether it’s an appropriate option with their healthcare provider. This article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: FDA approves Lilly’s Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions – Eli Lilly

  • FDA Weighs Interim Access Pathway for Compounded Peptides

    Encouraging news is emerging from regulatory circles: the FDA is reportedly considering an interim access pathway for compounded peptides, a move that could help maintain patient access to these therapies while broader regulatory frameworks continue to take shape. For patients and practitioners who have come to rely on compounded peptide formulations, this development signals that regulators may be listening to concerns about continuity of care.

    Compounded peptides have become an important option for many patients, particularly when commercially manufactured versions are unavailable, in short supply, or not yet approved for certain uses. An interim access framework, if finalized, would represent a thoughtful middle path—allowing the FDA to maintain appropriate oversight of safety and quality while giving patients and prescribers more certainty during the agency’s ongoing evaluation process.

    This kind of regulatory flexibility is notable because it reflects a collaborative approach rather than an abrupt restriction. Rather than an all-or-nothing stance, an interim pathway suggests the FDA may be working toward solutions that balance public health safeguards with real-world patient needs. For the broader peptide therapeutics space, this is a hopeful sign that regulators recognize the value these compounds can offer when manufactured and dispensed responsibly.

    The same news roundup also highlighted a label expansion for Enspryng, underscoring a broader trend of regulatory bodies continuing to refine and broaden the ways approved therapies can help patients. Together, these developments point to a regulatory environment that, while cautious, is actively working to keep beneficial treatment options accessible.

    As this situation develops, patients and healthcare providers interested in compounded peptides should stay tuned for official FDA guidance and consult qualified medical professionals about what any changes might mean for their specific treatment plans. This article is for informational purposes only and is not medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: FDA considers interim access for compounded peptides; Enspryng’s label expansion – Endpoints News

  • Antimicrobial Peptide Spray PL-5 Shows Promise in Speeding Healing of Infected Burn Wounds

    Burn wounds that become infected can be especially difficult to treat, often requiring prolonged care and raising concerns about antibiotic-resistant bacteria. New results from a late-stage clinical trial of an antimicrobial peptide spray called PL-5 offer encouraging news for patients facing this challenge, suggesting the treatment may help infected burn wounds heal more quickly than standard approaches.

    PL-5 belongs to a class of compounds known as antimicrobial peptides, which are naturally inspired molecules that can target and disrupt harmful bacteria. Unlike many conventional antibiotics, these peptides work through mechanisms that may make it harder for bacteria to develop resistance, a growing concern in wound care and infectious disease treatment more broadly. Delivered as a topical spray, PL-5 is designed to be applied directly to the wound site, potentially simplifying treatment for both patients and healthcare providers.

    According to the reported late-stage trial findings, patients treated with the PL-5 spray experienced faster healing of infected burn wounds compared to those who did not receive it. Faster wound closure is clinically meaningful because it can reduce the risk of further complications, shorten hospital stays, and improve overall recovery experiences for burn patients, who often face painful and lengthy treatment courses.

    The development of effective topical antimicrobial peptide therapies like PL-5 reflects a broader and growing interest in peptide-based solutions as alternatives or complements to traditional antibiotics. Researchers have been exploring antimicrobial peptides for years due to their unique ability to target bacterial membranes directly, and positive late-stage trial data represents an important step toward potentially bringing such therapies into everyday clinical use. If further validated, this approach could eventually provide clinicians with another valuable option for managing difficult-to-treat burn infections.

    While these results are promising, continued research, regulatory review, and additional data will help determine how PL-5 might fit into future burn care protocols. The peptide field continues to generate exciting developments like this one, highlighting the ongoing potential of peptide science to address persistent medical challenges. As always, this article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Antimicrobial Peptide Spray PL-5 Speeds Healing of Infected Burn Wounds in Late-Stage Trial – bioengineer.org

  • New Clinical Trial Explores Smooth Transition to Next-Generation Peptide Therapy Zenagamtide

    New Clinical Trial Explores Smooth Transition to Next-Generation Peptide Therapy Zenagamtide

    A newly launched clinical trial is investigating how adults living with overweight or obesity—some of whom also manage type 2 diabetes—respond when transitioning from their current tirzepatide treatment to a new investigational therapy called zenagamtide. The study represents an encouraging step forward in the ongoing development of peptide-based metabolic treatments, offering researchers valuable insight into how patients can potentially move between therapies safely and effectively.

    Tirzepatide has already established itself as a widely used treatment option for weight management and blood sugar control. This new research builds on that foundation by exploring zenagamtide, a next-generation peptide candidate, and specifically examining the practical question of how patients already stabilized on tirzepatide tolerate a switch. Understanding this transition process is important groundwork for expanding the toolkit of options available to patients and their healthcare providers.

    In this trial, all participants will receive both tirzepatide and zenagamtide, allowing researchers to directly observe tolerability and determine which zenagamtide dose level may appropriately correspond to a given maintenance dose of tirzepatide. This kind of dose-equivalence research is a valuable and often overlooked piece of the development puzzle—it helps pave the way for smoother, more confident transitions for patients down the line, should zenagamtide eventually become an approved option.

    Studies like this one reflect the broader momentum in the peptide therapeutics space, where researchers continue to refine and diversify treatment approaches for weight management and metabolic health. By focusing specifically on real-world scenarios—such as switching from an established therapy to a newer one—this research could help inform future clinical guidance and give patients more flexibility in how their care evolves over time.

    While results from this trial are not yet available, its design signals a thoughtful, patient-centered approach to advancing peptide science. True North Labs will continue to follow this study as it progresses and share updates as findings emerge. This article is for informational purposes only and is not medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Clinical Trial: A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Tirzepatide Medication

  • New Trial Explores Peptide-Dye Combination to Help Surgeons See Cancer More Clearly

    New Trial Explores Peptide-Dye Combination to Help Surgeons See Cancer More Clearly

    Researchers have launched a Phase 1 clinical trial to study nivolumab-IRDye800CW (nivo800), an innovative imaging agent designed to help surgeons more precisely visualize head and neck squamous cell carcinoma (HNSCC) tumors during surgery. The trial combines nivolumab, a well-known immunotherapy antibody, with IRDye800CW, a fluorescent dye, creating a tool that could potentially light up cancerous tissue in real time for surgical teams.

    The study will enroll adults with biopsy-confirmed or presumed HNSCC who are already scheduled for standard-of-care surgical removal of their tumors. Participants will receive two intravenous infusions of the imaging agent before their operation — one about two to three weeks prior, and another just one to two days before surgery. This timing allows researchers to study how the compound distributes within tumor tissue and surrounding structures over different time windows.

    Beyond simply testing safety, the trial has a valuable secondary goal: evaluating pathological response in surgically removed tissue. By examining residual tumor, fibrosis, necrosis, and immune cell activity (specifically tumor-infiltrating lymphocytes) in different dose groups, researchers hope to learn more about how the body responds to the combination agent at a cellular level. This kind of detailed analysis could offer broader insights into immune engagement with HNSCC tumors, a cancer type where improved visualization during surgery could support more complete tumor removal.

    Fluorescence-guided surgery is an area of growing interest because it has the potential to give surgeons additional real-time visual information beyond what the eye alone can detect. If nivo800 proves safe and feasible in this early-phase study, it could pave the way for larger trials exploring whether this type of imaging approach helps improve surgical precision for head and neck cancer patients in the future.

    This early-stage trial reflects the kind of methodical, safety-first research that underpins advances in cancer care. As with all Phase 1 studies, the primary focus is on safety and feasibility rather than definitive clinical benefit, and results will take time to emerge. This article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Clinical Trial: Safety and Feasibility of Nivolumab-IRDye800CW in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC)

  • New Clinical Trial Compares Firsekibart to Anakinra for Adult-Onset Still’s Disease

    New Clinical Trial Compares Firsekibart to Anakinra for Adult-Onset Still’s Disease

    A newly registered clinical trial is set to compare firsekibart, an investigational therapy, against anakinra, a well-established treatment, in adults living with Adult-Onset Still’s Disease (AOSD). This rare autoinflammatory condition, which causes symptoms such as high fevers, joint pain, and skin rashes, has limited treatment options, making research like this especially valuable for patients and clinicians alike.

    The study aims to directly measure both the efficacy and safety of the two therapies head-to-head, a research design that can provide clearer, more actionable insights than studies that only test a single treatment against a placebo. For people managing AOSD, head-to-head comparisons like this can be particularly helpful in guiding future treatment decisions, since they offer real data on how newer options stack up against medications already in use.

    Anakinra has served as an important option for AOSD patients for years, and having it as the comparator speaks to confidence in its track record while also opening the door for investigating whether firsekibart can offer meaningful benefits, whether that means comparable results with a different safety profile, improved symptom control, or other advantages for patients.

    Trials of this kind represent the ongoing effort within the medical research community to refine and expand care for people with rare and chronic inflammatory conditions. Even before results are available, the existence of this study is a positive sign: it reflects continued investment in understanding AOSD and a commitment to giving patients more evidence-based choices for managing their condition over time.

    As with any clinical trial, results will take time, and outcomes are not guaranteed. Patients interested in learning more about trial eligibility or participation should speak with their healthcare provider. This article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Clinical Trial: A Study of Firsekibart Versus Anakinra in Adult-Onset Still’s Disease

  • FDA Grants Temporary Enforcement Reprieve for Peptide Compounding, Preserving Patient Access

    Compounding pharmacies and the patients who rely on them received encouraging news this week with reports of a temporary enforcement reprieve from the U.S. Food and Drug Administration regarding certain peptide compounding practices. According to legal analysis from Buchanan Ingersoll & Rooney PC, the FDA’s approach signals a willingness to give the compounding industry more time to adjust before stricter enforcement measures take full effect.

    Peptide compounding has become an increasingly important part of personalized medicine, allowing pharmacies to prepare customized formulations for patients with specific needs that commercial products may not address. A temporary pause in stringent enforcement gives pharmacies breathing room to align their practices with evolving federal guidance, while continuing to serve patients who depend on these specialized preparations.

    For many patients, compounded peptides represent an important option when commercially manufactured alternatives are unavailable, discontinued, or not suited to their particular circumstances. By easing the immediate regulatory pressure, the FDA’s reprieve helps maintain continuity of care during this transitional period, giving healthcare providers and pharmacists more certainty as they navigate compliance requirements.

    Industry attorneys note that this kind of temporary relief often reflects ongoing dialogue between regulators and the compounding community, suggesting that final rules may ultimately be shaped with practical input from pharmacies, prescribers, and patient advocates. This collaborative approach can lead to more workable long-term policies that balance patient safety with access to needed therapies.

    While the regulatory landscape for peptide compounding continues to evolve, this reprieve is a welcome signal that the FDA is taking a measured approach rather than an abrupt crackdown. Pharmacies and patients alike can view this as an opportunity for the industry to demonstrate strong quality and safety practices while broader standards are finalized. This article is for informational purposes only and is not medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: FDA Peptide Compounding Policy: What a Temporary Enforcement Reprieve Could Mean for Pharmacies – Buchanan Ingersoll & Rooney PC

  • Teitur Trophics Reports Successful Phase I Trial Results for Novel Peptide Therapy

    Teitur Trophics Reports Successful Phase I Trial Results for Novel Peptide Therapy

    Peptide therapeutics continue to show promise, with biotechnology company Teitur Trophics announcing successful results from its Phase I clinical trial. While detailed data points have not yet been fully disclosed, the company’s announcement signals that its investigational peptide candidate met key early-stage safety and tolerability benchmarks, an important milestone on the path toward further clinical development.

    Phase I trials are typically the first opportunity to evaluate how a new compound behaves in human participants, with a primary focus on safety, dosing, and how the body processes the treatment. A successful outcome at this stage is a meaningful achievement, as it allows a therapeutic candidate to advance toward larger studies that can begin to assess effectiveness in treating specific conditions.

    This announcement is part of a broader wave of positive developments in the peptide research space, where companies around the world are exploring these compact, naturally inspired molecules for their potential to address a wide range of health challenges. Peptides are valued by researchers for their specificity and their ability to mimic or modulate natural biological processes, which can translate into therapies with favorable safety profiles when properly developed and tested.

    For Teitur Trophics, this milestone represents validation of its research and development approach and may pave the way for continued investment and advancement of its pipeline. Successful Phase I results often serve as a confidence-building step for companies seeking to progress into Phase II trials, where researchers begin to more closely examine how well a treatment works for its intended use.

    As peptide-based science continues to mature, announcements like this highlight the ongoing innovation within the field and the dedication of research teams working to bring new therapeutic options forward. True North Labs will continue to follow Teitur Trophics’ progress as more details emerge from this promising program.

    This article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Teitur Trophics announces successful results from Phase I – GlobeNewswire